Revolutionizing Stroke Treatment Through Innovative Technology

Advancements in Stroke Care Technology

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments.

Brainomix, a global leader in AI-driven stroke imaging, has achieved a significant milestone by receiving FDA clearance for a patented feature that allows physicians to assess ischemic core volume using readily available non-contrast CT (NCCT) images through the Brainomix 360 Stroke solution. This pivotal enhancement addresses a long-standing need in stroke triage, enabling healthcare professionals across various networks to gain vital insights that can significantly improve treatment decisions and patient transfers based on routine brain scans.

Impact on Stroke Treatment

The core volume feature has undergone extensive validation by renowned stroke centers in the US, demonstrating its effectiveness compared to traditional CT Perfusion and MRI-derived assessments. "This key expansion of our Brainomix 360 platform signifies a strategic advancement in the field of stroke imaging. Our mission is to transform stroke care with cutting-edge technology. Brainomix 360 gives stroke teams real-time, high-precision insights, providing patients with access to crucial treatments like thrombolysis and mechanical thrombectomy up to 24 hours after the onset of a stroke," expressed Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix.

Noteworthy Study Findings

Brainomix 360 stands out as the only stroke AI imaging tool that has shown a measurable impact on stroke treatment rates. A comprehensive evaluation gathering national-level data from over 450,000 patients over three years revealed that Brainomix 360 contributed to a remarkable more than 50% increase in mechanical thrombectomy rates.

Dr. Mehdi Bouslama, a specialist in Neuroendovascular Surgery and Vascular Neurology, co-authored a pivotal study published in the journal Stroke. Alongside Dr. Raul Nogueira and researchers from Emory University, he established the efficacy of Brainomix's NCCT core volume. "The ability of Brainomix 360 to reliably estimate ischemic core volumes comparably to CT Perfusion offers an exciting alternative for centers lacking advanced imaging tools or specialists in imaging interpretation. This could broaden access to endovascular therapies," he remarked.

Comparable Performance with Established Imaging Tools

Another vital study, co-authored by Dr. Kambiz Nael from the University of California, San Francisco, was published in the Journal of Neurointerventional Surgery (JNIS) and confirmed the equivalence of Brainomix NCCT core volumes with those derived from concurrent CT Perfusion. The study’s conclusion highlighted the algorithm's remarkable capability to assess ischemic core volumes from NCCT images, aligning closely with traditional imaging techniques and suggesting its attractiveness for centers with limited access to advanced imaging modalities.

Upcoming Educational Webinar

Dr. Bouslama and Dr. Nael will participate in an informative webinar titled "Imaging the Core on NCCT: Unlocking Stroke Insights Across Networks," set to take place on the upcoming Thursday at 12pm EST. This session aims to further educate participants on these significant advancements in stroke imaging.

About Brainomix

Brainomix is at the forefront of innovation, developing AI-powered software solutions designed to optimize precision medicine, particularly in stroke care and lung fibrosis treatment. Born from a spinout initiative at the University of Oxford, Brainomix has grown into a thriving commercial enterprise with a presence in over 20 countries, including the UK, Ireland, and the USA. As a private company supported by leading healthtech investors, Brainomix has pioneered award-winning imaging biomarkers and software systems that are widely used in hospitals worldwide. Their flagship product, the Brainomix 360 stroke platform, delivers the most comprehensive stroke imaging capabilities available, driving increased treatment rates and enhancing patient outcomes.

Frequently Asked Questions

What is the significance of Brainomix 360 receiving FDA clearance?

This clearance allows physicians to utilize innovative technology for assessing ischemic core volumes from basic brain scans, enhancing decision-making in stroke care.

How does Brainomix 360 improve stroke treatment rates?

By providing accurate imaging assessments, it facilitates timely and effective treatments like mechanical thrombectomy, leading to improved patient outcomes.

What are the benefits of using non-contrast CT scans?

Non-contrast CT scans are widely available, making them a practical option for quick assessments in emergency settings, which is crucial during stroke events.

Who are the key researchers involved with Brainomix 360?

Notable contributors include Dr. Mehdi Bouslama and Dr. Kambiz Nael, who have published significant studies validating the effectiveness of the technology.

How can I learn more about Brainomix and its solutions?

Visiting Brainomix's website provides comprehensive information on their technologies and solutions that target stroke care improvements.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.